

1614
Docket No.: PF-0420
514

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231 on July 17, 2002.

By: Margaret M. Hasson Printed: Margaret M. Hasson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Magna et al.

Title: HUMAN NUCLEOTIDE PYROPHOSPHOHYDROLASE-2

Serial No.: 09/757,716

Filing Date: January 09, 2001

Examiner: Decloux, A.

Group Art Unit: 1644

RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard; and
2. Response to Restriction Requirement (8 pp.).

COPY OF PAPERS
ORIGINALLY FILED

The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present-Extra	Other Than Small Entity Rate	Fee	Additional Fee(s)
Total	20	-	23		0	x\$18.00		\$ 0
Indept.	3	-	3		0	x\$84.00		\$ 0
First Presentation of Multiple Dependent Claims						+280.00		\$ 0
Total Fee:								\$ 0

X No additional Fee is required.

 Please charge Deposit Account No. **09-0108** in the amount of : \$

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

INCYTE GENOMICS, INC.


Date: July 17, 2002

Jenny L. Buchbinder
Jenny L. Buchbinder

Reg. No. 48,588

Direct Dial Telephone: (650) 843-7212

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166



ket No.: PF-0420-2 DIV

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Box Non-Fee Amendment** Commissioner for Patents, Washington, D.C. 20231 on July 17, 2002.

B1:

Printed: Margaret M. Hasson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 25 2002
TECH CENTER 1600/290

In re Application of: Magna et al.

Title: HUMAN NUCLEOTIDE PYROPHOSPHOHYDROLASE-2

Serial No.: 09/757,716

Filing Date: January 09, 2001

Examiner: Decloux, A.

Group Art Unit: 1644

COPY OF PAPERS
ORIGINALLY FILED

Box Non-Fee Amendment

Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

Sir:

This paper is responsive to the Restriction Requirement dated June 17, 2002, setting a **one (1) month** term for response. Prior to examination of the application, please amend the specification of the above-identified application as listed below.

IN THE CLAIMS

Please cancel claims 1, 10, and 29-44 without prejudice or disclaimer.

Please add the following new claims 45-64.

For the Examiner's convenience, all pending claims are listed below. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."